What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2020-09-10 compared with 2019-09-12 · 333 added, 282 removed, 44 unchanged (93% of the section changed)

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

shares trade on the Nasdaq Capital Market under the symbol PSTI and in the Tel Aviv Stock Exchange under the ticker symbol PLTR.

of September 4, 2019, there were 111 holders of record, and 15,547,621 of our common shares were issued and outstanding.

shares of common stock trade on the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol PSTI.

of September 4, 2020, there were 101 holders of record, and 25,554,668 shares of our common stock were issued and outstanding.

Stock Transfer and Trust Company, LLC is the registrar and transfer agent for our common shares.

6 unchanged sentences

and hematologic conditions.

Our lead indications are CLI, recovery following surgery for hip fracture and ARS.

Each of these indications

is a severe unmet medical need.

cells are derived from a class of placental cells that are harvested from donated placenta at the time of full term healthy delivery

PLX cell products require no tissue matching prior to administration.

Our operations are focused on the research, development, manufacturing, conducting clinical trials

and business development of cell therapeutics and related technologies.

We are currently enrolling

patients in two Phase III studies:

one for CLI and another for muscle recovery following surgery for hip fracture.

we are focusing on other indications such as ARS, incomplete recovery following bone marrow transplantation, Steroid-Refractory

cGVHD and IC.

We received clearance from the FDA and the PEI to conduct a Phase II study evaluating PLX cells for the treatment

of severe cases of the COVID-19 complicated by ARDS.

We have treated several patients in Israel and in the United States suffering

from severe ARDS associated with COVID-19 under a compassionate use program.

In addition, the FDA has cleared our EAP for the use

of our PLX-PAD cells to treat up to 100 patients suffering from ARDS caused by COVID-19 outside of our ongoing Phase II COVID-19

study in the U.S.

We believe that each of these indications is a severe unmet medical need.

PLX cells are derived from

a class of placental cells that are harvested from donated placenta at the time of full term healthy delivery of a baby.

products require no tissue or blood matching prior to administration.

They are produced using our proprietary three-dimensional

expansion technology.

Our manufacturing facility complies with the European, Japanese, Israeli and FDA’s current Good Manufacturing

Practice requirements and has been approved by the European and Israeli regulators for production of PLX-PAD for late stage trials

and marketing.

In December 2017, after an audit of our facilities, we were granted manufacturer/importer authorization and Good

Manufacturing Practice Certification by Israel’s Ministry of Health.

If we obtain FDA and other regulatory approvals to

market PLX cells, we expect to have in-house production capacity to grow clinical-grade PLX cells in commercial quantities.

goal is to make significant progress with our clinical pipeline and our clinical pivotal trials in order to ultimately bring innovative,

Our manufacturing facility complies with the European, Japanese, Israeli, South Korean and the FDA’s

cGMP requirements and has been inspected and approved by the European and Israeli regulators for production of PLX-PAD for late

stage trials.

We have also granted manufacturer/importer authorization and cGMP Certification by Israel’s Ministry of Health.

If we obtain FDA and other regulatory approvals to market PLX cells, we expect to have in-house production capacity to grow PLX

cells in commercial quantities.

Research and Development - In-House Clinical Manufacturing”

for additional

goal is to make significant progress with our clinical pipeline and our clinical trials in order to ultimately bring innovative,

potent therapies to patients who need new treatment options.

We expect to demonstrate a real-world impact and value from our clinical

pipeline, technology platform and commercial-scale manufacturing capacity.

Our business model for commercialization and revenue

generation includes, but is not limited to, direct sale of our products, partnerships, licensing deals, and joint ventures with

pharmaceutical companies.

aim to shorten the time to commercialization of our product candidates, by leveraging unique accelerated regulatory pathways that

exist in the United States, Europe and other territories to bring innovative products that address life-threatening diseases to

the market efficiently.

have determined to invest our resources primarily on the PLX-PAD Phase III clinical trials relating to CLI and muscle recovery

following surgery for hip fracture, and focus on finalizing the clinical trials in the United States, Europe and Israel while

we prepare for the marketing phase, with the initiation of such marketing phase subject to regulatory approval, in these territories.

pivotal, Phase III multinational clinical trials are currently conducted with our PLX-PAD product candidate:

one in CLI, and the

other in recovery following surgery for hip fracture.

second product candidate, PLX-R18, is under development in the United States for ARS via the FDA Animal Rule regulatory pathway,

which may result in approval under the Animal Rule, without the performance of human efficacy trials.

We expect to demonstrate a real-world impact and value from our pipeline,

technology platform and commercial-scale manufacturing capacity.

Our business model for commercialization and revenue generation

includes, but is not limited to, direct sale of our products, partnerships, licensing deals, and joint ventures with pharmaceutical

were incorporated in Nevada in 2001, and we have a wholly owned subsidiary in Israel called Pluristem Ltd.

and a wholly owned

subsidiary in Germany called Pluristem GmbH.

OF OPERATIONS –

3 unchanged sentences

years ended June 30, 2020 and June 30, 2019 were related to the sale of our PLX cells for research use.

of revenues for the year ended June 30, 2019 and June 30, 2018 were $2,000.

All cost of revenues are related to the royalties

we are obligated to pay to the IIA.

of revenues for the year ended June 30, 2019 were $2,000 compared to no cost of revenues for the year ended June 30, 2020.

cost of revenues are related to the royalties we are obligated to pay to the IIA.

and Development, Net

and development net costs (costs less participation and grants by the IIA, Horizon 2020 and other parties) for the year ended

June 30, 2019 increased by 17% to $26,427,000 from $22,629,000 for the year ended June 30, 2018.

The increase is mainly attributed

(1) an increase in subcontractor expenses related to some of our clinical trials, (2) an increase in materials consumption

due to high volume of production of our products for clinical trials, (3) a decrease in IIA participation (approximately $900,000

was approved in calendar year 2018 compared to approximately $500,000 that was approved in calendar year 2019), and (4) an increase

in stock-based compensation expenses due to the amount of restricted stock units, or RSUs, and options granted.

The increase was

partially offset due to grants received from the Israel-United States Binational Industrial Research and Development Foundation,

or BIRD, and from Indiana University, and due to a decrease in payroll expenses related to differences in exchange rates.

and Administrative

and administrative expenses decreased by 18% from $11,193,000 for the year ended June 30, 2018 to $9,157,000 for the year ended

June 30, 2019.

This decrease is attributed to a decrease in stock-based compensation expenses related to the amount of RSUs granted

and their vesting schedules, a decrease in corporate activities expenses and a decrease in payroll expenses related to differences

in exchange rates.

income decreased from $7,605,000 for the year ended June 30, 2018 to $225 for the year ended June 30, 2019.

This decrease is mainly

due to the sale of our investments in marketable securities which occurred in the year ended June 30, 2018 that resulted a net

gain of $7,606,000.

loss for the year ended June 30, 2019 was $35,307,000 as compared to a net loss of $26,126,000 for the year ended June 30, 2018.

The changes were mainly due to a decrease in financial income, net, and increases in research and development expenses for the

reasons mentioned above.

Net loss per share for the year ended June 30, 2019 was $2.90, as compared to $2.50 for the year ended

June 30, 2020 decreased by 18% to $21,577,000 from $26,427,000 for the year ended June 30, 2019.

The decrease is mainly attributed

to (1) our increasingly efficient production activities that resulted in a decrease in materials consumption, (2) a decrease in

payroll expenses related to a decrease in the average number of employees and temporary salary deductions during April and May

2020 (as part of our expense reduction strategy due to COVID-19), (3) a decrease in stock-based compensation expenses related

to the amount of restricted stock units, or RSUs, granted and their vesting schedules, (4) a decrease in expenses related to clinical

site initiation and (5) a decrease in rent expenses due to the implementation of Accounting Standards Update No.

2016-02, “Leases,”

which resulted in a reduction of $160,000 (for further information please refer to Note 7 in the accompanying financial statements

to this Annual Report).

The decrease was partially offset by lower participation by the European Union with respect to the Horizon

2020 grants, which was primarily utilized in the first year of the projects, and a lower participation by the IIA due to a decrease

in the grant obtained in calendar year 2020 compared to calendar year 2019 and to calendar year 2018.

General and Administrative

General and administrative expenses decreased

by 13% from $9,157,000 for the year ended June 30, 2019 to $7,922,000 for the year ended June 30, 2020.

This decrease is attributed

to a decrease in stock-based compensation expenses related to the amount of RSUs granted and their vesting schedules, a decrease

in payroll expenses related to a 25% reduction of the annual salary of our CEO and, a 25% reduction of the annual compensation

of our Executive Chairman and temporary salary deductions during April and May 2020 (as part of our expense reduction strategy

due to COVID-19).

The decrease was partially offset by an increase in professional services expenses related to the EIB Agreement.

Financial Income, Net

Financial income increased from $225,000

for the year ended June 30, 2019 to $324,000 for the year ended June 30, 2020.

This increase is mainly attributable to increased

income from exchange rates related to the strength of the U.S.

dollar against the NIS and changes in the fair value of our hedging

instruments related to the strength of the U.S.

dollar against the NIS, partially offset by financial expense from the implementation

of Accounting Standards Update No.

2016-02, “Leases,”

which resulted in an expense of $261,000 (for further information

please refer to Note 7 in the accompanying financial statements to this Annual Report).

Net loss for the year ended June 30, 2020

was $29,152,000 as compared to a net loss of $35,307,000 for the year ended June 30, 2019.

The changes were mainly due to a decrease

in research and development expenses, net, and a decrease in general and administrative expenses, net for the reasons mentioned

Net loss per share for the year ended June 30, 2020 was $1.60 per share, as compared to $2.90 per share for the year ended

June 30, 2019.

The net loss per share increased mainly as a result of an increase in the net loss, offset by an increase in our

weighted average number of shares due to the issuance of additional shares during fiscal year 2019.

and Capital Resources

of June 30, 2019, our total current assets were $26,371,000 and our total current liabilities were $8,158,000.

On June 30, 2019,

we had a working capital surplus of $18,213,000 and an accumulated deficit of $251,004,000.

of June 30, 2018, our total current assets were $32,036,000 and our total current liabilities were $8,548,000.

On June 30, 2018,

we had a working capital surplus of $23,488,000 and an accumulated deficit of $215,697,000.

cash and cash equivalents and restricted cash as of June 30, 2019 amounted to $5,186,000.

This is a decrease of $4,701,000 from

the $9,887,000 reported as of June 30, 2018.

Cash balances decreased in the year ended June 30, 2019 for the reasons presented

activities used cash of $29,453,000 in the year ended June 30, 2019.

Cash used by operating activities in the year ended June

30, 2019 primarily consisted of payments to subcontractors, suppliers, and professional services providers primarily related to

our ongoing Phase III clinical trials and payments of salaries to our employees, offset by participation of the IIA, Horizon 2020

and other grants.

activities provided cash of $1,170,000 in the year ended June 30, 2019.

The investing activities in the year ended June 30, 2019

consisted primarily of cash provided from repayment of short term deposits of $1,415,000, offset by payments of $239,000 related

to investments in property and equipment and Investment in restricted bank deposits of $6,000.

activities generated cash in the amount of $23,582,000 during the year ended June 30, 2019.

The cash generated in the year ended

June 30, 2019 from financing activities is related to net proceeds of $19,464,000 from issuing shares of our common stock in a

public offering we conducted in April 2019, net proceeds of $4,003,000 from issuing shares of our common stock under our At Market

Sales Agreement, or the ATM Agreement, with FBR Capital Markets & Co., MLV & Co.

The net loss per share decreased mainly as a result of an increase in our weighted average number of shares due

to the issuance of additional shares issued during fiscal year 2020, and by a decrease in the net loss.

Liquidity and Capital Resources

As of June 30, 2020, our total current assets

were $48,461,000 and our total current liabilities were $7,987,000.

On June 30, 2020, we had a working capital surplus of $40,474,000

and an accumulated deficit of $280,156,000.

As of June 30, 2019, our total current assets

were $26,371,000 and our total current liabilities were $8,158,000.

On June 30, 2019, we had a working capital surplus of $18,213,000

and an accumulated deficit of $251,004,000.

Our cash and cash equivalents and restricted

cash as of June 30, 2020 amounted to $9,229,000.

This is a decrease of $4,043,000 from the $5,186,000 reported as of June 30, 2019.

Cash balances decreased in the year ended June 30, 2020 for the reasons presented below.

Operating activities used cash of $26,369,000

in the year ended June 30, 2020.

Cash used by operating activities in the year ended June 30, 2020 primarily consisted of payments

to subcontractors, suppliers, and professional services providers primarily related to our ongoing clinical trials and payments

of salaries to our employees, offset by participation of the IIA, Horizon 2020 and other grants.

Investing activities used cash of $30,458,000

in the year ended June 30, 2020.

The investing activities in the year ended June 30, 2020 consisted primarily of cash used for

investment in short-term deposits of $17,949,000, investment in long-term deposits of $12,239,000 and payments of $270,000 related

to investments in property and equipment.

Financing activities generated cash in the

amount of $60,870,000 during the year ended June 30, 2020.

The cash generated in the year ended June 30, 2020 from financing activities

is related to net proceeds of $43,262,000 from issuing shares of our common stock under our Sales Agreement (defined below), net

proceeds of $14,901,000 from issuing shares of our common stock in a registered direct offering in May 2020 and net proceeds of

$2,707,000 from issuing shares of our common stock from the exercise of warrants.

On February 6, 2019, we entered into an

Open Market Sales Agreement SM , or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we may issue

and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through Jefferies.

We are not obligated to make any sales of common stock under the Sales Agreement.

From February 6, 2019 through June 30, 2020,

we sold an aggregate of 8,297,750 shares of common stock pursuant to the Sales Agreement for aggregate gross proceeds of $ 49,140,965.

On June 30, 2020, our shelf registration on Form S-3 declared effective by the SEC on June 23, 2017 expired, and as a result thereof,

the parties stopped utilizing the Sales Agreement.

On July 16, 2020, we entered into a new Open Market Sales Agreement SM ,

or the 2020 Sales Agreement, with Jefferies, pursuant to which we may issue and sell shares of our common stock having an aggregate

offering price of up to $75,000,000 from time to time through Jefferies.

Upon entering into the 2020 Sales Agreement, we filed

a new shelf registration statement on Form S-3, which was declared effective by the SEC on July 23, 2020.

In the year ended June 30, 2020, warrants

to purchase up to 386,678 shares from our April 2019 firm commitment public offering, or the 2019 Public Offering, were exercised

by investors at an exercise price of $7.00 per share, resulting in the issuance of 386,678 shares of common stock for net proceeds

of approximately $2,707,000.

On May 5, 2020, we entered into a securities

purchase agreement with two institutional investors, or the Investors, pursuant to which we sold, in a registered direct offering

to the Investors, 1,587,302 shares of common stock for net proceeds of approximately $14,901.

On April 30, 2020, we and our Israeli subsidiary,

Pluristem Ltd., and our German subsidiary, Pluristem GmbH, entered into the EIB Agreement with the EIB, pursuant to which we can

obtain a loan in the amount of Euro 50 million, or the Loan, payable in tranches, subject to the achievement of certain clinical,

regulatory and scale up milestones.

Each of the Company and Pluristem Ltd.

are guarantors under the Finance Contract.

is not secured and will be disbursed in three tranches consisting of one tranche of Euro 20 million, or the First Tranche, a second

tranche of Euro 18 million, or the Second Tranche, and a third tranche of Euro12 million, or the Third Tranche, each as may be

requested by us, subject to the achievement of clinical, regulatory and scale up milestones.

The tranches will be treated independently,

each with its own interest rate and maturity period.

The fixed interest rate is 0% per annum for the First Tranche and 1.00% for

each of the Second Tranche and Third Tranche.

The deferred interest rate is 4% per annum for the First Tranche, 3% for the Second

Tranche and 2% for the Third Tranche.

We are required to repay the First Tranche and the Second Tranche, with all other amounts

owed thereunder, in a single installment on the maturity date of that tranche, following the five-year anniversaries from each

of the First Tranche and the Second Tranche disbursements.

We are required to repay the Third Tranche, with all other amounts owed

thereunder, in two equal installments, with the first such payment following the fourth anniversary of the disbursement date and

the last repayment on a date not later than five years from the disbursement date.

To date, we have not yet received a disbursement

pursuant to the EIB Agreement.

During the year ended

June 30, 2020, we received cash of approximately $23,000 from third parties from the sale of our PLX cells for research use.

Our cash and cash equivalents and restricted

cash as of June 30, 2019 amounted to $5,186,000.

This is a decrease of $4,701,000 from the $9,887,000 reported as of June 30, 2018.

Cash balances decreased in the year ended June 30, 2019 for the reasons presented below.

Operating activities used cash of $29,453,000

in the year ended June 30, 2019.

Cash used by operating activities in the year ended June 30, 2019 primarily consisted of payments

to subcontractors, suppliers, and professional services providers primarily related to our ongoing Phase III clinical trials and

payments of salaries to our employees, offset by participation of the IIA, Horizon 2020 and other grants.

Investing activities provided cash of $1,170,000

in the year ended June 30, 2019.

The investing activities in the year ended June 30, 2019 consisted primarily of cash provided

from repayment of short term deposits of $1,415,000, offset by payments of $239,000 related to investments in property and equipment

and Investment in restricted bank deposits of $6,000.

Financing activities generated cash in the

amount of $23,582,000 during the year ended June 30, 2019.

The cash generated in the year ended June 30, 2019 from financing activities

is related to net proceeds, after deducting underwriting commissions and discounts, and other offering expenses, of $19,464,000

from issuing shares of our common stock in the Public Offering and Registered Direct Offering (as defined below), aggregate net

proceeds of $4,003,000 from issuing shares of our common stock under our (1) At Market Sales Agreement, or the ATM Agreement, with

FBR Capital Markets & Co., MLV & Co.

LLC and Oppenheimer & Co.

the Sales Agreement, proceeds of $107,000 related to a grant received from BIRD and net proceeds of $8,000 from the exercise of

July 2017, we entered into the ATM Agreement with FBR Capital Markets & Co., MLV & Co.

Inc., and (2) the Sales Agreement, proceeds of $107,000

related to a grant received from the Israel-United States Binational Industrial Research and Development Foundation and net proceeds

of $8,000 from the exercise of options.

In July 2017, we entered into the ATM Agreement

with FBR Capital Markets & Co., MLV & Co.

LLC and Oppenheimer & Co.

each an Agent, which provided that, upon the terms and subject to the conditions and limitations set forth in the ATM Agreement,

we could elect, from time to time, to issue and sell shares of common stock having an aggregate offering price of up to $80,000,000

through any of the Agents.

We were not obligated to make any sales of common stock under the ATM Agreement.

From July 2017 through

February 4, 2019, we sold an aggregate of 530,541 shares of common stock pursuant to the ATM Agreement at an average price of

$13.70 per share.

On February 4, 2019, we notified the Agents of the termination of the ATM Agreement.

February 6, 2019, we entered into a Sales Agreement with Jefferies LLC, pursuant to which we may issue and sell shares of our

common stock having an aggregate offering price of up to $50,000,000 from time to time through Jefferies.

We are not obligated

to make any sales of common stock under the Sales Agreement.

From February 6, 2019 through June 30, 2019, we sold an aggregate

of 236,800 shares of common stock pursuant to the Sales Agreement at an average price of $9.70 per share.

April 8, 2019, we sold, pursuant to an underwriting agreement relating to a firm commitment public offering, or the Public Offering,

an aggregate of 2,857,143 shares of common stock and warrants to purchase up to 2,857,143 shares of common stock, inclusive of

the underwriter’s over-allotment option which was exercised in full, for aggregate gross proceeds of $20,000,000.

issued in the Public Offering are exercisable for a period of five years from issuance and have an exercise price of $7.00 per

In addition, on April 8, 2019, we sold, pursuant to a subscription agreement with a certain investor in a registered direct

offering, or the Registered Direct Offering, 142,857 shares of common stock, for aggregate gross proceeds of $1,000,000.

proceeds from the Public Offering and the Registered Direct Offering, after deducting underwriting commissions and discounts,

and other offering expenses, were $19,464,000.

the year ended June 30, 2019, we received cash of approximately $54,000 from third parties from the sale of our PLX cells for

research use.

cash and cash equivalents as of June 30, 2018 amounted to $8,821,000.

This is an increase of $4,114,000 from the $4,707,000 reported

as of June 30, 2017.

Cash balances increased in the year ended June 30, 2018 for the reasons presented below.

activities used cash of $21,380,000 in the year ended June 30, 2018.

Cash used by operating activities in the year ended June

30, 2018 primarily consisted of payments of salaries to our employees, and payments of fees to our consultants, suppliers, subcontractors,

and professional services providers including the costs of clinical trials, offset by IIA and Horizon 2020 grants.

activities provided cash of $5,573,000 in the year ended June 30, 2018.

The investing activities in the year ended June 30, 2018

consisted primarily of cash provided from the sale and the redemption of marketable securities of $21,890,000, offset by investments

in short term deposits of $14,829,000, investment of $1,146,000 in marketable securities and payments of $342,000 related to investments

in property and equipment.

activities generated cash in the amount of $19,921,000 during the year ended June 30, 2018.

The financing activities are primarily

attributable to net proceeds of $13,646,000 from issuing shares of our common stock in a public offering we conducted in Israel

in October 2017, net proceeds of $1,202,000 from issuing shares of our common stock from the exercise of warrants and options,

net proceeds of $4,985,000 from issuing shares of our common stock under the ATM Agreement and proceeds of $88,000 related to

a grant received from BIRD.

of June 30, 2018, we had sold 359,941 shares of common stock under the ATM Agreement, at an average price of $14.30 per share.

October 31, 2017, we completed a public offering in Israel, pursuant to our existing shelf registration statement in the United

States and a shelf registration statement filed in Israel, pursuant to which we raised aggregate gross proceeds of $15,051,000

through the sale of 900,000 shares of our common stock at a purchase price of NIS 59 (approximately $16.70 per share).

proceeds, after deducting fees and expenses related to the offering, were $13,646,000.

the year ended June 30, 2018, we received cash of approximately $50,000 from a third party from the sale of our PLX cells for

research use.

the year ended June 30, 2018, we were awarded approximately $43,000 (NIS 150,000) by the Israeli Ministry of Labor, Social Affairs

and Social Services related to an “Equal Employment”

program which aims to reward and honor Israeli employers who

demonstrate and promote gender equality in employment.

the years ended June 30, 2019 and 2018, we received approximately $550,000 and $2,328,000, respectively, in cash from the IIA

towards our research and development expenses.

to the IIA grant terms, we are required to pay royalties at a rate of 3% on sales of products and services derived from technology

developed using this and other IIA grants until 100% of the dollar-linked grants amount plus interest are repaid.

In the absence

of such sales, no payment is required.

During the year ended June 30, 2019, we paid $2,000 of royalties to the IIA.

impose certain conditions on any arrangement under which the IIA permits the Company to transfer technology or development out

of Israel or outsource manufacturing out of Israel.

While the grant is given to the Company over a certain period of time (usually

a year), the requirements and restrictions under the Israeli Law for the Encouragement of Industrial Research and Development,

1984 continue and do not have a set expiration period, except for the royalties, which requirement to pay them expires after payment

the years ended June 30, 2019 and 2018, we received total cash grants of approximately $1,374,000 and $2,265,000, respectively,

from the European Union research and development consortiums relating to the Horizon 2020 program.

accordance with the CHA Agreement, in December 2013, we issued to CHA 250,000 shares of our common stock in consideration for

the issuance to us of 1,011,504 common shares of CHA, which reflected total consideration of approximately $10,414,000 to each

of us and CHA.

The parties also agreed to give an irrevocable proxy to the other party’s management with respect to the

shares issued.

March 2015, we sold a portion of the CHA shares received in December 2013, resulting in net proceeds of $5,717,000.

was $282,000 and was presented as “Financial income, net”

in fiscal 2015.

January 2018, we sold the remainder of our holdings in CHA, consisting of 400,368 shares of CHA, on the open market for aggregate

net proceeds of approximately $10,500,000, representing a net gain of $6,200,000 presented in “Financial income, net”.

IIA has supported our activity in the past fourteen years.

Our last program, for the fourteenth year, was approved by the IIA

in 2019 and relates to a grant of approximately $500,000.

The grant will be used to cover research and development expenses for

the period January 1, 2019 to December 31, 2019.

July 2018, we were awarded a marketing grant of approximately $52,000 under the “Shalav”

program of the Israeli Ministry

of Economy and Industry.

The grant is intended to facilitate certain marketing and business development activities with respect

to our advanced cell therapy products in the U.S.

July 2017, we were awarded an additional Smart Money grant of approximately $229,000 from Israel’s Ministry of Economy.

The Israeli government granted us budget resources that we intend to use to advance our product candidate towards marketing in

China-Hong Kong markets.

We will also receive close support from Israel’s trade representatives stationed in China, including

Hong Kong, along with experts appointed by the Smart Money program.

August 2016, our CLI program in the European Union was awarded a Euro 7,600,000 (approximately $8,700,000) grant.

part of the European Union’s Horizon 2020 program.

The Phase III study of PLX-PAD in CLI will be a collaborative project

carried out by an international consortium led by the Berlin-Brandenburg Center for Regenerative Therapies together with the Company

and with participation of additional third parties.

Inc., each an Agent, which provided that, upon

the terms and subject to the conditions and limitations set forth in the ATM Agreement, we could elect, from time to time, to issue

and sell shares of common stock having an aggregate offering price of up to $80,000,000 through any of the Agents.

obligated to make any sales of common stock under the ATM Agreement.

From July 2017 through February 4, 2019, we sold an aggregate

of 530,541 shares of common stock pursuant to the ATM Agreement at an average price of $13.70 per share.

On February 4, 2019, we

notified the Agents of the termination of the ATM Agreement.

From February 6, 2019 through June 30, 2019,

we sold an aggregate of 236,800 shares of common stock pursuant to the Sales Agreement at an average price of $9.70 per share.

On April 8, 2019, we sold, pursuant to an

underwriting agreement relating to the 2019 Public Offering, an aggregate of 2,857,143 shares of common stock and warrants to purchase

up to 2,857,143 shares of common stock, inclusive of the underwriter’s over-allotment option which was exercised in full,

for aggregate gross proceeds of $20,000,000.

The warrants issued in the Public Offering are exercisable for a period of five years

from issuance and have an exercise price of $7.00 per share.

In addition, on April 8, 2019, we sold, pursuant to a subscription

agreement with a certain investor in a registered direct offering, or the Registered Direct Offering, 142,857 shares of common

stock, for aggregate gross proceeds of $1,000,000.

The net proceeds from the Public Offering and the Registered Direct Offering,

after deducting underwriting commissions and discounts, and other offering expenses, were $19,464,000.

During the year ended June 30, 2019, we

received cash of approximately $54,000 from third parties from the sale of our PLX cells for research use.

During the years ended June 30, 2020 and

2019, we received total cash grants of approximately $1,227,000 and $1,374,000, respectively, from the European Union research

and development consortiums relating to the Horizon 2020 program.

Non-dilutive grants

The IIA has supported

our activity during the past 14 years.

Our last program was approved by the IIA in 2019 and relates to a grant of approximately

The grant was used to cover research and development expenses for the period January 1, 2019 to December 31, 2019.

According to the IIA grant terms, we are

required to pay royalties at a rate of 3% on sales of products and services derived from technology developed using this and other

IIA grants until 100% of the dollar-linked grants amount plus interest are repaid.

In the absence of such sales, no payment is

During the year ended June 30, 2020, no royalties were paid to the IIA.

The IIA may impose certain conditions on any

arrangement under which the IIA permits the Company to transfer technology or development out of Israel or outsource manufacturing

out of Israel.

While the grant is given to the Company over a certain period of time (usually a year), the requirements and restrictions

under the Israeli Law for the Encouragement of Industrial Research and Development, 1984 continue and do not have a set expiration

period, except for the royalties, which requirement to pay them expires after payment in full.

In May 2020, we were

selected as a member of the CRISPR-IL consortium, a group funded by the IIA.

CRISPR-IL brings together the leading experts in life

science and computer science from academia, medicine, and industry, to develop AI based end-to-end genome-editing solutions.

is funded by the IIA with a total budget of approximately $10,000,000 of which, an amount of approximately $480,000 is a direct

grant allocated to us, for a period of 18 months, with a potential for extension of an additional 18 months and additional budget

from the IIA.

CRISPR-IL participants include leading companies, and medical and academic institutions.

In July 2018, we were

awarded a marketing grant of approximately $52,000 under the “Shalav”

program of the Israeli Ministry of Economy and

The grant is intended to facilitate certain marketing and business development activities with respect to our advanced

cell therapy products in the U.S.

In July 2017, we were

awarded an additional Smart Money grant of approximately $229,000 from Israel’s Ministry of Economy.

The Israeli government

granted us budget resources that we intend to use to advance our product candidate towards marketing in China-Hong Kong markets.

We will also receive close support from Israel’s trade representatives stationed in China, including Hong Kong, along with

experts appointed by the Smart Money program.

In August 2016, our

CLI program in the European Union was awarded a Euro 7,600,000 (approximately $8,500,000) grant.

The grant is part of the European

Union’s Horizon 2020 program.

The Phase III study of PLX-PAD in CLI will be a collaborative project carried out by an international

consortium led by the Berlin-Brandenburg Center for Regenerative Therapies together with the Company and with participation of

additional third parties.

The grant will cover a significant portion of the CLI program costs.

of Euro 1,900,000 (approximately $2,200,000) is a direct grant allocated to us, and the Company also expects to benefit from cost

savings resulting from grant amounts allocated to the other consortium members.

In July 2017, the consortium amended the consortium

agreement, pursuant to which the original grant allocation was amended such that we will receive an additional direct grant of

Euro 1,000,000 (approximately $1,100,000).

The additional direct grant was allocated to us from the total amount of the original

September 2017, our Phase III study of PLX-PAD cell therapy in the treatment of muscle injury following surgery for hip fracture

was awarded a Euro 7,400,000 (approximately $8,400,000) grant, as part of the European Union’s Horizon 2020 program.

Phase III study will be a collaborative project carried out by an international consortium led by Charité, together with

us, and with participation of additional third parties.

An amount of Euro 1,900,000 (approximately

$2,100,000) is a direct grant allocated to us, and the Company also expects to benefit from cost savings resulting from grant amounts

allocated to the other consortium members.

In July 2017, the consortium amended the consortium agreement, pursuant to which the

original grant allocation was amended such that we will receive an additional direct grant of Euro 1,000,000 (approximately $1,100,000).

The additional direct grant was allocated to us from the total amount of the original grant.

In September 2017,

our Phase III study of PLX-PAD cell therapy in the treatment of muscle injury following surgery for hip fracture was awarded a

Euro 7,400,000 (approximately $8,300,000) grant, as part of the European Union’s Horizon 2020 program.

This Phase III study

will be a collaborative project carried out by an international consortium led by Charité, together with us, and with participation

of additional third parties.

The grant will cover a significant portion of the project costs.

of Euro 2,550,000 (approximately $2,900,000) is a direct grant allocated to us for manufacturing and other costs, and we also

expect to have a direct benefit from cost savings resulting from grant amounts allocated to the other consortium members.

October 2017, the nTRACK, a collaborative project carried out by an international consortium led by Leitat was awarded a Euro

6,800,000 (approximately $7,700,000) non-royalty bearing grant.

An amount of Euro 500,000 (approximately $570,000) is a direct

grant allocated to us.

We also expect to benefit from cost savings resulting from grant amounts allocated to the other consortium

adhere to an investment policy set by our investment committee which aims to preserve our financial assets, maintain adequate

liquidity and maximize return while minimizing exposure to the NIS.

Such policy further provides that we should hold most of our

current assets in bank deposits and the remainder of our current assets is to be invested in other low risk instruments.

today, the currency of our financial portfolio is mainly in U.S.

dollars and we use options contracts in order to hedge our exposures

have accumulated a deficit of $251,004,000 since our inception in May 2001.

We do not expect to generate any significant revenues

from sales of products in the next twelve months.

It is possible that our cash needs will increase in the foreseeable future.

We expect to generate revenues, which in the short and medium terms will unlikely exceed our costs of operations, from the sale

of licenses to use our technology or products.

We will be required to obtain additional liquidity resources in order to support

the commercialization of our products and maintain our research and development and clinical trials activities.

of June 30, 2019, our cash position (cash and cash equivalents, short-term bank deposits and restricted cash and long-term bank

deposits) totaled approximately $24,795,000.

We are addressing our liquidity issues by implementing initiatives to allow the continuation

of our activities.

Our current operating plan includes various assumptions concerning the level and timing of cash outflows for

operating activities and capital expenditures.

ability to successfully carry out our business plan, which includes a cost-reduction plan should we be unable to raise sufficient

additional capital, is primarily dependent upon our ability to (1) obtain sufficient additional capital, (2) entering into license

agreements to use or commercialize our products and (3) receive other sources of funding, including non-diluting sources such

as the IIA grants, the Horizon 2020 grants and other grants.

There are no assurances, however, that we will be successful in obtaining

an adequate level of financing needed for the long-term development and commercialization of our products.

to our management’s estimates, liquidity resources as of June 30, 2019, together with the funds received under the Sales

Agreement during July and August 2019, will be sufficient to maintain our operations into the first quarter of fiscal year 2021.

Our inability to raise funds to carry out our business plan will have a severe negative impact on its ability to remain a viable

These conditions raise substantial doubt about our ability to continue as a going concern.

of Critical Accounting Policies

significant accounting policies are more fully described in Note 2 to our consolidated financial statements appearing in this

Annual Report.

We believe that the accounting policies below are critical for one to fully understand and evaluate our financial

condition and results of operations.

discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared

in accordance with U.S.

An amount of Euro 2,550,000 (approximately

$2,900,000) is a direct grant allocated to us for manufacturing and other costs, and we also expect to have a direct benefit from

cost savings resulting from grant amounts allocated to the other consortium members.

In October 2017, the

nTRACK, a collaborative project carried out by an international consortium led by Leitat was awarded a Euro 6,800,000 (approximately

$7,600,000) non-royalty bearing grant.

An amount of Euro 500,000 (approximately $560,000) is a direct grant allocated to us.

also expect to benefit from cost savings resulting from grant amounts allocated to the other consortium members.

We have accumulated a deficit of $280,156,000

since our inception in May 2001.

We do not expect to generate any significant revenues from sales of products in the next twelve

Our cash needs may increase in the foreseeable future.

We expect to generate revenues, from the sale of licenses to use

our technology or products, but in the short and medium terms will unlikely exceed our costs of operations.

We may be required to obtain additional

liquidity resources in order to support the commercialization of our products and maintain our research and development and clinical

trials activities.

We are continually looking for sources

of funding, including non-diluting sources such as the EIB Financing, the IIA grants, the European Union grant and other research

grants, collaboration with other companies and sales of our common stock.

We believe that we have sufficient cash

to fund our operations for at least the next 12 months.

Application of Critical Accounting Policies

Our significant accounting

policies are more fully described in Note 2 to our consolidated financial statements appearing in this Annual Report.

that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of

The discussion and

analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance

generally accepted accounting principles.

The preparation of these financial statements requires us to

make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the reported revenues and

expenses during the reporting periods.

On an ongoing basis, we evaluate such estimates and judgments, including those described

in greater detail below.

We base our estimates on historical experience and on various other factors that we believe are reasonable

under the circumstances.

The preparation of these financial statements requires us to make estimates

and assumptions that affect the reported amounts of assets and liabilities, as well as the reported revenues and expenses during

the reporting periods.

On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail

We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances.

Actual results may differ from these estimates under different assumptions or conditions.

compensation is considered critical accounting policy due to the significant expenses of RSUs which were granted to our employees,

directors and consultants.

In fiscal year 2019, we recorded stock-based compensation expenses related to options, restricted stock

and RSUs in the amount of $5,146,000.

accordance with ASC 718, “Compensation-Stock Compensation”, or ASC 718, restricted share units granted to employees

and directors are measured at their fair value on the grant date.

All restricted shares units granted in 2019 and 2018 were granted

for no consideration;

therefore their fair value was equal to the share price at the date of grant, based on the close trading

price of our shares known at the grant date.

The restricted shares units to non-employees consultants are remeasured in any future

vesting period for the unvested portion of the grants.

value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods

in our consolidated statements of operations.

We have graded vesting based on the accelerated method over the requisite service

period of each of the awards.

Stock-Based Compensation

Stock-based compensation

is considered a critical accounting policy due to the significant expenses of RSUs which were granted to our employees, directors

and consultants.

In fiscal year 2020, we recorded stock-based compensation expenses related to options, restricted stock and RSUs

in the amount of $2,561,000.

In accordance with

ASC 718, “Compensation-Stock Compensation”, or ASC 718, RSUs granted to employees and directors are measured at their

fair value on the grant date.

All RSUs granted in fiscal years 2020 and 2019 were granted for no consideration;

therefore their

fair value was equal to the share price at the date of grant, based on the close trading price of our shares known at the grant

The RSUs granted in fiscal year 2019 to non-employees consultants were remeasured in any future vesting period for the unvested

portion of the grants.

The RSUs granted in fiscal year 2020 to non-employees consultants were measured at their fair value on the

grant date in accordance with ASU No.

2018-07 - “Compensation—Stock Compensation”

The value of the portion

of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in our consolidated

statements of operations.

We have graded vesting based on the accelerated method over the requisite service period of each of the

The expected pre-vesting forfeiture rate affects the number of the shares.

Based on our historical

experience, the pre-vesting forfeiture rate per grant is 7% for the shares granted to employees and 0% for the shares granted

to our directors, CEO, Executive Chairman and non-employees consultants.

and Development Expenses, Net

expect our research and development expenses to remain our primary expense in the near future as we continue to develop our product

Our research and development expenses consist primarily of clinical trials expenses, consultant and subcontractor

expenses, payroll and related expenses, lab material expenses, stock based compensation expenses, rent and maintenance expenses

and patent expenses.

The following table provides a breakdown of the related costs for fiscal years 2017 through 2019 (in thousands

Based on our historical experience, the pre-vesting

forfeiture rate per grant is 7% for the shares granted to employees and 0% for the shares granted to our directors, CEO, Executive

Chairman and non-employee consultants.

Research and Development Expenses, Net

We expect our research

and development expenses to remain our primary expense in the near future as we continue to develop our product candidates.

research and development expenses consist primarily of clinical trials expenses, consultant and subcontractor expenses, payroll

and related expenses, lab material expenses, stock-based compensation expenses, rent and maintenance expenses and patent expenses.

The following table provides a breakdown of the related costs for fiscal years 2018 through 2020 (in thousands of dollars):

Year ended June 30,

11 unchanged sentences

Research and development expenses, net

invest heavily in research and development.

Research and development expenses, net, were our major operating expenses, representing

74%, 67% and 75% of the total operating expenses for each of our fiscal years 2019, 2018 and 2017, respectively.

We expect that

in the upcoming years our research and development expenses, net, will continue to be our major operating expense.

following summarizes our contractual obligations and other commitments on June 30, 2019, and the effect such obligations could

have on our liquidity and cash flow in future periods:

We invest heavily in research and development.

Research and development expenses, net, were our major operating expenses, representing 73%, 74% and 67% of the total operating

expenses for each of our fiscal years 2020, 2019 and 2018, respectively.

We expect that in the upcoming years our research and

development expenses, net, will continue to be our major operating expense.

Contractual Obligations

The following summarizes our contractual

obligations and other commitments on June 30, 2020, and the effect such obligations could have on our liquidity and cash flow in

future periods:

Payments due by period

Contractual Obligations

Less than 1 year

More than 5 years

Operating lease obligations

Minimum purchase requirements

Accrued severance pay, net

Balance Sheet Arrangements

have no off balance sheet arrangements.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity